These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 3280680)

  • 1. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
    Kasid A; Bell GI; Director EP
    J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated effector cells: modulation of activity by cytokines.
    Mehta S; Flanagan P; Blackinton D; Wanebo H
    Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS; Scuderi P; Grimes WJ; Hersh EM
    J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
    Koberda J; Przepiorka D; Moser RP; Grimm EE
    Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.
    Jin B; Scott JL; Vadas MA; Burns GF
    Immunology; 1989 Apr; 66(4):570-6. PubMed ID: 2541074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
    Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
    J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
    Ostensen ME; Thiele DL; Lipsky PE
    J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.
    Jelinek DF; Lipsky PE
    J Immunol; 1987 Nov; 139(9):2970-6. PubMed ID: 3117883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
    Nishimura T; Burakoff SJ; Herrmann SH
    J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of biological response modifiers on lung natural killer activity.
    Lauzon W; Lemaire I
    Immunopharmacol Immunotoxicol; 1991; 13(3):237-50. PubMed ID: 1719060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
    Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
    Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4.
    Salvucci O; Mami-Chouaib F; Moreau JL; Thèze J; Chehimi J; Chouaib S
    Eur J Immunol; 1996 Nov; 26(11):2736-41. PubMed ID: 8921963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS; Hargrove ME; Ting CC
    J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.